v3.26.1
Earnings Per Common Share And Share Awards Summary Of Share-Based Award Transactions (Details) - SARs - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2026
Dec. 31, 2025
Dec. 31, 2024
Share-based Compensation Arrangement by Share-based Payment Award, SARS, Outstanding [Roll Forward]      
Number of shares, outstanding beginning balance 24 28  
Number of shares, SARs granted 0 5  
Number of shares, SARS exercised (1) (9)  
Number of shares, outstanding ending balance 23 24 28
Number of shares, exercisable as of March 31, 2026 21    
Number of shares, unvested as of March 31, 2026 2    
Share-based Compensation Arrangement by Share-based Payment Award, SARs, Outstanding, Weighted Average Exercise Price [Roll Forward]      
Weighted average exercise price, outstanding beginning balance $ 170.67 $ 154.74  
Weighted average exercise price, SARs granted 0 246.75  
Weighted average exercise price, SARS exercised 162.55 158.04  
Weighted average exercise price, outstanding ending balance 171.21 $ 170.67 $ 154.74
Weighted average exercise price, exercisable as of March 31, 2026 173.78    
Weighted average exercise price, unvested as of March 31, 2026 $ 144.60    
Average remaining contractual term, outstanding beginning balance 3 years 10 months 24 days 3 years 10 months 28 days 3 years 10 months 24 days
Average remaining contractual term, outstanding ending balance 3 years 10 months 24 days 3 years 10 months 28 days 3 years 10 months 24 days
Average remaining contractual term, exercisable as of March 31, 2026 3 years 11 months 8 days    
Average remaining contractual term, unvested as of March 31, 2026 3 years 5 months 12 days    
Aggregate intrinsic value, outstanding beginning balance $ 2,312 $ 2,312  
Aggregate intrinsic value, outstanding ending balance 1,178 $ 2,312 $ 2,312
Aggregate intrinsic value, exercisable as of March 31, 2026 1,033    
Aggregate intrinsic value, unvested as of March 31, 2026 $ 145